About the Project
We recently identified a subset of CD206+ macrophages in chemotherapy-treated breast tumours that gather around blood vessels and drive relapse. Our latest data show that these cells are immunosuppressive and upregulate a protein called VISTA. This is a potent, broad-spectrum negative checkpoint regulator (NCR) that inhibits the anti-tumour functions of cytotoxic T cells (CTLs) in tumours. We believe that macrophages expressing high levels of VISTA in the perivascular niche of tumours after chemotherapy inhibit CTLs upon their entry into tumours, helping to protect cancer cells from destruction by the immune system, and facilitating tumour regrowth.
The PhD student will conduct experiments to see whether CD206-targeted liposomes containing an inhibitor for VISTA stimulates tumour CTLs after chemotherapy, augments anti-tumour immunity, and prevents subsequent relapse. The project will also investigate with these liposomes can augment the efficacy of checkpoint inhibitors like anti-PD1 and anti-PDL1. These new combination treatment treatments will be tested in various experimental models of TNBC and, if successful, will then progress into early-phase clinical trials for TNBC patients.
This project is open to self-funded students only.
Candidates must have a upper second class honors degree or equivalent overseas qualification, in a relevant subject.
Interested candidates should in the first instance contact (Professor Claire Lewis, +44 (0)114 215 9012 & [Email Address Removed])
Please complete a University Postgraduate Research Application form available here: www.shef.ac.uk/postgraduate/research/apply
Please clearly state the prospective main supervisor in the respective box and select 'Oncology and Metabolism' as the department.
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.